Metabolic disease, in particular type 2 diabetes, is one of the world’s greatest health challenges. There is a need to move from disease management to disease modification - potentially reversing the growing burden of this devastating condition. Fractyl Health is in late-stage clinical trials with an organ-editing metabolic therapy for type 2 diabetes. It is the first investigational disease-modifying procedure for this condition with the potential to prevent and arrest disease progression. Fractyl Health’s aim is to develop transformative therapies that ultimately prevent and eliminate metabolic disease.